Skip to content
Resources > Reports

Enterprise Software: Assessing AI Adoption Trends

By Michelle Brophy, Director of Research, Tech, Media and Telecom and Sean Carmichael

Generative AI is moving from isolated pilots to full-scale deployments, with adoption accelerating in areas like software development and IT service management. However, broad access to genAI tools hasn’t translated into consistent engagement. Most firms still lack the training, governance, and integration needed to realize full ROI.

This report examines where genAI is driving real, positive business outcomes and what separates successful enterprise-scale efforts from those that stall. Challenges like data security, accuracy, and scaling costs persist. The firms overcoming these challenges are those with structured data and repeatable workflows, which enable fast, measurable impact.

About the Authors
  • Michelle Brophy, Director of Research, Tech, Media and Telecom

    Michelle Brophy serves as the Director of Research, Tech, Media and Telecom at AlphaSense. Prior to joining AlphaSense, Michelle spent 3 years as the Strategist for TMT at Guidepoint Insights. Prior to this, Michelle spent 18 years on the buy side, in both portfolio manager and senior equity analyst roles, at Hilltop Park Capital and Kingdon Capital Management. Michelle resides in New York City.
  • Sean Carmichael

    Sean is a Business & Finance Editor at AlphaSense, specializing in sector-specific content production. Previously, he spent nearly a decade in various roles across financial services, where he was responsible for equity research and content generation geared toward institutional investors.

Explore more

From Promise to Performance: How AI Will Evolve in 2026

2025 was the year generative AI grew up, shifting from isolated experiments to integrated systems. What also emerged was a clearer picture of how AI will continue to mature in 2026.
Title slide: From Promise to Performance: How AI Will Evolve in 2026 by Sarah Hoffman, Director of AI Thought Leadership, with abstract tech graphics.

Most-Favored-Nation Policy: Implications for European Drug Launches

The U.S. shift toward most-favored-nation (MFN) drug pricing is forcing pharmaceutical firms to rethink their pricing models and launch strategies in Europe.
U.S. Most-Favored-Nation Drug Pricing Policy: What Does It Mean for Europe? by Sara Mallatt and Sean Carmichael, with a stylized map of Europe.

Navigating Biopharma Policy

Biopharma firms are grappling with a turbulent and complex policy landscape.
Title slide: Navigating Biopharma Policy 2025 Changes and a Look Ahead by Sara Mallatt and Sean Carmichael, featuring a flask and a Capitol building.

Transform intelligence
into advantage

Develop bold strategies, seize opportunities,
and lead with clarity and confidence.